Oria Bioscience

Oria Bioscience is transforming drug discovery for brain diseases by providing pharmaceutical companies with industrial-scale access to isolated organelles. Founded in 2023 by Dr. Alexandre Santinho, Dr. Abdou-Rachid Thiam, and Marine Moutia, Oria addresses a critical need for high-throughput screening of new therapeutic targets that were previously inaccessible. Its patented microfluidic technology produces millions of viable organelles, such as lysosomes and mitochondria, enabling more precise and faster testing of drug candidates.

Oria’s solution allows researchers to explore novel intracellular mechanisms involved in neurodegenerative and psychiatric diseases, helping reduce clinical trial failure rates and accelerate the development of innovative treatments. Already validated by major pharmaceutical groups, Oria is scaling production and expanding internationally to meet growing demand in Europe and the United States.